Bupropion: pharmacology and therapeutic applications.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review without systematic literature search or meta-analytic methodology.
PubMed 17009913 · doi:10.1586/14737175.6.9.1249
What was done
This narrative review summarizes the pharmacology, metabolism, mechanisms of action, adverse effect profile, and clinical indications of bupropion based on literature available 17 years after its introduction.
What was found
The abstract reports no numerical data or effect sizes. It reports that bupropion is metabolized to active 4-hydroxybupropion by CYP2B6, inhibits CYP2D6, and primarily acts via dopamine and norepinephrine reuptake inhibition alongside vesicular monoamine transporter-2 (VMAT-2) upregulation. Clinically, it has efficacy comparable to other antidepressants for major depression and seasonal affective disorder, is effective for smoking cessation, and works as an SSRI augment. Compared to SSRIs, it exhibits lower rates of nausea and the lowest rates of sexual dysfunction, with nervousness and insomnia as common side effects and seizure risk in overdose.
Why it matters
It provides a consolidated clinical overview of bupropion as a primary non-serotonergic antidepressant option, particularly valuable for patients experiencing SSRI-induced sexual dysfunction or seeking smoking cessation.
Limits
The abstract presents no quantitative data or systematic review methodology. Mentions of effects on inflammatory markers (TNF-alpha), cancer-related fatigue, and concentration rely on anecdotal reports.
Cited by
- supports Wellbutrin (bupropion) increases dopamine and norepinephrine broadly across the brain rather than targeting specific circuits.